



US011090294B2

(12) **United States Patent**
Baker et al.

(10) **Patent No.:** **US 11,090,294 B2**
(45) **Date of Patent:** **Aug. 17, 2021**

(54) **COMBINATIONS OF A MUSCARINIC
RECEPTOR ANTAGONIST AND A BETA-2
ADRENORECEPTOR AGONIST**

(71) Applicant: **Glaxo Group Limited**, Middlesex (GB)

(72) Inventors: **Darrell Baker**, Uxbridge (GB); **Mark
Bruce**, Stevenage (GB); **Glenn Crater**,
Mississauga (CA); **Brian Noga**,
Durham, NC (US); **Marian Thomas**,
Ware (GB); **Patrick Wire**, Durham, NC
(US)

(73) Assignee: **Glaxo Group Limited**, Middlesex (GB)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/678,246**

(22) Filed: **Aug. 16, 2017**

(65) **Prior Publication Data**

US 2018/0008582 A1 Jan. 11, 2018

Related U.S. Application Data

(63) Continuation of application No. 14/970,945, filed on
Dec. 16, 2015, now Pat. No. 9,750,726, which is a
continuation of application No. 13/510,962, filed as
application No. PCT/EP2010/068429 on Nov. 29,
2010, now abandoned.

(30) **Foreign Application Priority Data**

Dec. 1, 2009 (GB) 0921075.8

(51) **Int. Cl.**

A01N 43/00 (2006.01)
A61K 31/33 (2006.01)
A61K 31/439 (2006.01)
A61K 31/138 (2006.01)
A61K 45/06 (2006.01)
A61K 9/00 (2006.01)
B65D 75/36 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/439** (2013.01); **A61K 9/0075**
(2013.01); **A61K 31/138** (2013.01); **A61K**
45/06 (2013.01); **B65D 75/36** (2013.01)

(58) **Field of Classification Search**

CPC ... **A61K 31/439**; **A61K 9/0075**; **A61K 31/138**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,778,054 A 10/1988 Newell et al.
4,811,731 A 3/1989 Newell et al.
4,832,880 A 5/1989 Staniforth
4,994,276 A 1/1991 Baichwal et al.
5,004,614 A 4/1991 Staniforth
5,035,237 A 7/1991 Newell et al.
5,135,757 A 8/1992 Baichwal et al.
5,145,684 A 9/1992 Liversidge et al.

5,376,386 A 12/1994 Ganderton et al.
5,441,060 A 8/1995 Rose et al.
5,478,578 A 12/1995 Arnold et al.
5,503,662 A 4/1996 Berger
5,506,203 A 4/1996 Blackstrom et al.
5,560,490 A 10/1996 Chawla
5,590,645 A 1/1997 Davies et al.
5,626,871 A 5/1997 Makino et al.
5,642,728 A 7/1997 Anderson et al.
5,663,198 A 9/1997 Reul et al.
5,730,785 A 3/1998 Idol et al.
5,746,937 A 5/1998 McKedy et al.
5,829,434 A 11/1998 Ambrosio et al.
5,860,419 A 1/1999 Davies et al.
5,873,360 A 2/1999 Davies et al.
5,972,388 A 10/1999 Sakon et al.
6,032,666 A 3/2000 Davies et al.
6,103,141 A 8/2000 Incorvia et al.
6,119,853 A 9/2000 Garrill et al.
6,132,394 A 10/2000 Lankinen
6,153,224 A 11/2000 Staniforth
6,153,322 A 11/2000 Lee et al.
6,156,231 A 12/2000 McKedy
6,179,118 B1 1/2001 Garrill et al.
D440,874 S 4/2001 Shurtleff et al.
6,221,338 B1 4/2001 Staniforth
6,279,736 B1 8/2001 Hekal
6,315,112 B1 11/2001 Garrill et al.
6,321,747 B1 11/2001 Dmitrovic et al.
6,352,152 B1 3/2002 Anderson et al.
6,378,519 B1 4/2002 Davies et al.
6,378,579 B1 4/2002 Giltner
6,390,291 B1 5/2002 Garrill et al.
6,521,260 B1 2/2003 Staniforth
6,533,321 B2 3/2003 Class et al.
6,536,427 B2 3/2003 Davies et al.
6,537,983 B1 3/2003 Biggadike et al.
6,582,678 B2 6/2003 Staniforth
6,679,374 B2 1/2004 Garrill et al.
6,759,398 B2 7/2004 Biggadike
6,792,945 B2 9/2004 Davies et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2347856 5/2000
DE 10056855 A1 5/2002
DE 202005002409 U1 7/2005
DE 202005004659 U1 7/2005
EP 0069715 A1 1/1983

(Continued)

OTHER PUBLICATIONS

Aaron et al., Tiotropium in combination with placebo, salmeterol, or
fluticasone-salmeterol for treatment of chronic obstructive pulmo-
nary disease: a randomized trial. *Ann Intern Med.* Apr. 17,
2017;146(8):545-55.

(Continued)

Primary Examiner — Jean P Cornet

(74) *Attorney, Agent, or Firm* — James P. Riek

(57) **ABSTRACT**

Combinations of a muscarinic acetylcholine receptor
antagonist and a beta 2 agonist for inhaled administration via
the nose or mouth, and methods of using them are provided.

56 Claims, No Drawings